Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C … Read more
Cocrystal Pharma Inc (COCP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.202x
Based on the latest financial reports, Cocrystal Pharma Inc (COCP) has a cash flow conversion efficiency ratio of -0.202x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.55 Million) by net assets ($7.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cocrystal Pharma Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Cocrystal Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cocrystal Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cocrystal Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kavango Resources Plc
PINK:KVGOF
|
-0.224x |
|
Agripure Holdings Public Company Limited
BK:APURE
|
-0.003x |
|
Akin Tekstil AS
IS:ATEKS
|
0.001x |
|
EBANG INTL HLDGS (NEW) A
F:7EBA
|
N/A |
|
Hanoi Plastics JSC
VN:NHH
|
N/A |
|
Poxel S.A.
LSE:0RA2
|
-0.123x |
|
Aurora Labs Ltd
AU:A3D
|
-1.442x |
|
Huayi Tencent Entertainment Company Limited
PINK:HUYTF
|
N/A |
Annual Cash Flow Conversion Efficiency for Cocrystal Pharma Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of Cocrystal Pharma Inc from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.52 Million | $-16.48 Million | -1.731x | -211.42% |
| 2023-12-31 | $26.38 Million | $-14.67 Million | -0.556x | -2.61% |
| 2022-12-31 | $39.57 Million | $-21.43 Million | -0.542x | -230.30% |
| 2021-12-31 | $77.55 Million | $-12.72 Million | -0.164x | +12.40% |
| 2020-12-31 | $52.51 Million | $-9.83 Million | -0.187x | -207.94% |
| 2019-12-31 | $25.71 Million | $-1.56 Million | -0.061x | +50.94% |
| 2018-12-31 | $66.89 Million | $-8.29 Million | -0.124x | -89.24% |
| 2017-12-31 | $105.40 Million | $-6.90 Million | -0.065x | +54.27% |
| 2016-12-31 | $102.32 Million | $-14.65 Million | -0.143x | -132.67% |
| 2015-12-31 | $167.59 Million | $-10.32 Million | -0.062x | +93.19% |
| 2014-12-31 | $6.65 Million | $-6.01 Million | -0.903x | -219.17% |
| 2013-12-31 | $-6.03 Million | $-4.57 Million | 0.758x | +84.47% |
| 2012-12-31 | $-3.58 Million | $-1.47 Million | 0.411x | +170.34% |
| 2011-12-31 | $-2.77 Million | $-420.95K | 0.152x | +105.45% |
| 2010-12-31 | $6.93K | $-19.34K | -2.791x | -506.59% |
| 2009-12-31 | $54.54K | $-25.10K | -0.460x | -30.68% |
| 2008-12-31 | $95.34K | $-33.58K | -0.352x | -51.65% |
| 2007-12-31 | $147.13K | $-34.17K | -0.232x | -- |